<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065086</url>
  </required_header>
  <id_info>
    <org_study_id>CCR5370</org_study_id>
    <nct_id>NCT05065086</nct_id>
  </id_info>
  <brief_title>Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence</brief_title>
  <acronym>STORM</acronym>
  <official_title>Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective observational cohort study investigating Single modality Trans Oral Robotic&#xD;
      surgery for primary oropharyngeal cancer: exploring the impact of surgical Margins on local&#xD;
      disease recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The STORM study will examine transoral surgery performed before 31st July 2019. STORM is a&#xD;
      retrospective observational cohort study, involving international centres performing TORS for&#xD;
      primary OPSCC.&#xD;
&#xD;
      The main aim of this study is to explore the impact of surgical margins on local disease&#xD;
      recurrence in primary oropharyngeal squamous cell carci-noma treated with transoral robotic&#xD;
      surgery (TORS) without adjuvant therapy.&#xD;
&#xD;
      The primary objective is to report local recurrence-free survival. The primary endpoint will&#xD;
      be Local recurrence-free survival time.&#xD;
&#xD;
      The secondary objectives are to report overall survival, disease-specific survival and&#xD;
      disease-free survival, and to report post-operative haemor-rhage rates. The secondary&#xD;
      endpoints include Overall survival time, Dis-ease-specific survival time, Disease-free&#xD;
      survival time, Post-operative haemorrhage time.&#xD;
&#xD;
      Exploratory objective to identify a clinically relevant cut-off for surgical margins as a&#xD;
      predictor of local disease recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence-free survival time</measure>
    <time_frame>At 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>At 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival time</measure>
    <time_frame>At 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival time</measure>
    <time_frame>At 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative haemorrhage time</measure>
    <time_frame>Within 30 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of Primary OPSCC with Index cancer treated with TORS, without&#xD;
        adjuvant therapy, on or before 31st July 2019.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older.&#xD;
&#xD;
          -  Primary OPSCC.&#xD;
&#xD;
          -  Index cancer treated with TORS without adjuvant therapy.&#xD;
&#xD;
          -  Any post-operative TNM classification.&#xD;
&#xD;
          -  TORS performed on or before 31st July 2019.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  TORS preformed for diagnostic or palliative intentions.&#xD;
&#xD;
          -  Known distant metastasis at time of TORS.&#xD;
&#xD;
          -  Nasopharyngeal and thyroid cancers.&#xD;
&#xD;
          -  Patients undergoing neoadjuvant or adjuvant chemotherapy, biotherapy, immunotherapy or&#xD;
             radiotherapy to either the neck or primary site.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Hardman, MBChB</last_name>
    <phone>442073528171</phone>
    <email>johncharles.hardman@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy O'Reilly</last_name>
    <phone>020 8661 3567</phone>
    <email>amy.o'reilly@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinidh Paleri, MS FRCS</last_name>
      <phone>0207 808 2732</phone>
      <email>Vinidh.Paleri@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>John Hardman, MBChB</last_name>
      <email>John.Hardman@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Vinidh Paleri, MS FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary OPSCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

